Eli Lilly Buys Centessa for $7B Wakefulness Push
Indianapolis News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Eli Lillys $7B Deal for Centessa Pharmaceuticals: A Wake-Up Call for Narcolepsy and Beyond
Eli Lilly has made a significant move in the pharmaceutical industry with a $7B acquisition of Centessa Pharmaceuticals, a biotech company specializing in wakefulness drugs for narcolepsy and daytime sleepiness. Centessa is currently developing a new class of medications in clinical trials, which could potentially address sleep issues linked to larger health concerns like Alzheimers. The deal includes an upfront payment of $6.3B and an additional $1.5B if the FDA approves their drugs. Shareholders will vote later this year, making this a deal to watch as it could shape Eli Lillys future in neurology.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/d1d97cef745a3b20